BioLineRx Ltd. business relationships

Companies named in BioLineRx Ltd.’s 20-F filed 2026-03-23, and public companies whose annual reports name BioLineRx Ltd.. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.

Open on the map Full AI visibility profile

AEO visibility: 6.1 / 10
AI naming: 100 / 100
Agent readiness: 0 / 100
AI adoption: 0 / 100

Named in BioLineRx Ltd.’s annual report 4

BlackRock, Inc. (BLK)Licensor7.7
“In November 2024, in connection with the Ayrmid License Agreement, the Company entered into an amendment to the loan Agreement with BlackRock.” SEC filing
BlackRock, Inc. (BLK)Supplier7.7
“cash provided by financing activities in 2024 primarily reflects the net proceeds of a loan from BlackRock and the net proceeds of a registered” SEC filing
Merck & Co., Inc. (MRK)Supplier7.7
“Amendment No. 2 to Clinical Trial Collaboration and Supply Agreement entered into as of July 24, 2018 between the Registrant and Merck Sharp & Dohme B.V.” SEC filing
Biokine Therapeutics Ltd.Licensor4.7
“$ 15.0 million associated with BL-8040 were recorded following an amendment to the in-licensing agreement with Biokine Therapeutics Ltd. ("Biokine").” SEC filing

Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.